Popular Pre-Market Trades in U.S. Stocks
Euda Health, down 7.08% in pre-market trading, has no significant recent news. The trading is active with clear capital flow, and considering the sector and industry trends, the stock shows significant volatility, with specific reasons needing further observation.
Top Gainers in U.S. Pre-Market Stocks
cbdMD up 107.61% in pre-market trading. Based on recent key news:
<ol>
<li>
On December 12, the U.S. President plans to change cannabis-related regulations through an executive order, which, while not directly legalizing or decriminalizing, will make it easier for related businesses to sell cannabis products and promote research on cannabis effects. As a CBD distributor, cbdMD's stock price has risen as a result. Source: Benzinga
</li>
<li>
On December 9, cbdMD announced it has resumed compliance with the continued listing standards of NYSE American, addressing all related deficiencies, which led to a rise in stock price. Source: Company announcement
</li>
<li>
On December 8, cbdMD disclosed its compliance status with the U.S. Securities and Exchange Commission in its annual and quarterly reports, highlighting future risks. Source: Company announcement. Changes in cannabis industry policies affect market sentiment.
</li>
</ol>
Akanda, up 60.22% in pre-market trading, has no significant recent news. The trading is active with clear capital flow, and considering the sector and industry trends, the stock shows significant volatility, with specific reasons needing further observation.
Tilray up 39.38% in pre-market trading. Based on recent key news:
<ol>
<li>
On December 12, Tilray announced the launch of Amped Live Resin Liquid Diamond 1g 510 cartridges, marking the Redecan brand's first entry into the active resin liquid diamond product line. This move enhances product innovation, attracting investor attention and driving up the stock price.
</li>
<li>
On December 12, market expectations for changes in cannabis industry policies have increased, potentially leading to a more stable operating environment. Analysts believe this will aid the long-term development of the industry, resulting in a significant rise in Tilray's stock price.
</li>
<li>
On December 11, Tilray released news about a new product line, further solidifying its market position, boosting investor confidence, and driving up the stock price. Expectations for changes in cannabis industry policies have increased
</li>
</ol>

EUDA

Euda Health pre-market down 7.08%; cbdMD pre-market up 107.61%; Akanda pre-market up 60.22%; Tilray pre-market up 39.38%

Pre-market hot trades in US stocks: Euda Health plummets 7.08% in pre-market, with active capital flow attracting market attention